Aptevo Therapeutics Inc.
APVO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $3,951 | $2,969 | $11,031 |
| - Cash | $21,061 | $9,410 | $2,139 | $8,714 |
| + Debt | $3,990 | $4,209 | $4,422 | $4,629 |
| Enterprise Value | – | -$1,250 | $5,252 | $6,946 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | -$71 |
| % Margin | – | – | – | – |
| EBITDA | -$7,500 | -$6,177 | -$6,419 | -$6,311 |
| % Margin | – | – | – | – |
| Net Income | -$7,549 | -$6,204 | -$6,408 | -$6,312 |
| % Margin | – | – | – | – |
| EPS Diluted | -2.23 | -8.4 | -87.87 | -86.56 |
| % Growth | 73.5% | 90.4% | -1.5% | – |
| Operating Cash Flow | -$6,688 | -$7,093 | -$6,575 | -$5,759 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$6,688 | -$7,093 | -$6,575 | -$5,759 |